Literature DB >> 3307623

Oral ribavirin treatment of influenza A and B.

D S Stein, C M Creticos, G G Jackson, J M Bernstein, F G Hayden, G M Schiff, D I Bernstein.   

Abstract

A loading dose and short-term administration of oral ribavirin significantly improved symptoms and signs of influenza type A or B infection in 25 patients. The antiviral effect was not significant. No adverse clinical effects or significant laboratory values were observed. Oral treatment of patients with influenza A or B infection might be possible with ribavirin.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3307623      PMCID： PMC174922          DOI： 10.1128/AAC.31.8.1285

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Sensitivity of influenza A virus to amantadine.

Authors:  G G Jackson
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

2.  Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man.

Authors:  W L Wingfield; D Pollack; R R Grunert
Journal:  N Engl J Med       Date:  1969-09-11       Impact factor: 91.245

3.  Occurrence of amantadine- and rimantadine-resistant influenza A virus strains during the 1980 epidemic.

Authors:  H Heider; B Adamczyk; H W Presber; C Schroeder; R Feldblum; M K Indulen
Journal:  Acta Virol       Date:  1981-11       Impact factor: 1.162

4.  Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers.

Authors:  C R Magnussen; R G Douglas; R F Betts; F K Roth; M P Meagher
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

5.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

6.  Ribavirin small-particle aerosol treatment of influenza.

Authors:  V Knight; H W McClung; S Z Wilson; B K Waters; J M Quarles; R W Cameron; S E Greggs; J M Zerwas; R B Couch
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

7.  Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection.

Authors:  C B Smith; R P Charette; J P Fox; M K Cooney; C E Hall
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

8.  Aminoadamantane-resistant strains of influenza A2 virus.

Authors:  J S Oxford; C W Potter
Journal:  J Hyg (Lond)       Date:  1973-06

9.  Lassa fever. Effective therapy with ribavirin.

Authors:  J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

10.  Successful treatment of naturally occurring influenza A/USSR/77 H1N1.

Authors:  L P Van Voris; R F Betts; F G Hayden; W A Christmas; R G Douglas
Journal:  JAMA       Date:  1981-03-20       Impact factor: 56.272
View more
  18 in total

Review 1.  The threat of avian influenza A (H5N1). Part III: Antiviral therapy.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-12       Impact factor: 3.402

2.  Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.

Authors:  Won-Young Kim; Gee Young Suh; Jin Won Huh; Sung-Han Kim; Min-ju Kim; Yun Seong Kim; Hye-Ryoun Kim; Yon Ju Ryu; Min Soo Han; Young Gwan Ko; Gyu Rak Chon; Kwan Ho Lee; Sang-Ho Choi; Sang-Bum Hong
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

3.  Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.

Authors:  Evelien Vanderlinden; Bram Vrancken; Jeroen Van Houdt; Vivek K Rajwanshi; Sarah Gillemot; Graciela Andrei; Philippe Lemey; Lieve Naesens
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Scott A Harper; John S Bradley; Janet A Englund; Thomas M File; Stefan Gravenstein; Frederick G Hayden; Allison J McGeer; Kathleen M Neuzil; Andrew T Pavia; Michael L Tapper; Timothy M Uyeki; Richard K Zimmerman
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

Review 5.  The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design.

Authors:  Annelies Stevaert; Lieve Naesens
Journal:  Med Res Rev       Date:  2016-08-29       Impact factor: 12.944

Review 6.  Recent progress in anti-influenza chemotherapy.

Authors:  S Shigeta
Journal:  Drugs R D       Date:  1999-09

Review 7.  Current and future antiviral therapy of severe seasonal and avian influenza.

Authors:  John Beigel; Mike Bray
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

Review 8.  Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.

Authors:  Daniel Todt; Stephanie Walter; Richard J P Brown; Eike Steinmann
Journal:  Viruses       Date:  2016-10-13       Impact factor: 5.048

Review 9.  Antiviral combinations for severe influenza.

Authors:  Jake Dunning; J Kenneth Baillie; Bin Cao; Frederick G Hayden
Journal:  Lancet Infect Dis       Date:  2014-09-08       Impact factor: 25.071

Review 10.  Antiviral therapy for respiratory tract infections.

Authors:  Samson S Y Wong; Kwok-Yung Yuen
Journal:  Respirology       Date:  2008-11       Impact factor: 6.424
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.